Hearing aids (with hearing loss) for Tinnitus: What Does the Evidence Show?
Hearing Technology · Ranked #6 on our Top 10 (weighting-sensitive)
Current evidence
If you have hearing loss with tinnitus, treating the hearing loss is one of the most effective single moves.
Evidence strength: Moderate (3/5) · Tier 2 — promising · Evidence independence: Primarily independent.
Properly fitted amplification for coexisting hearing loss — the AAO-HNSF guideline recommends a hearing aid evaluation whenever hearing loss accompanies bothersome tinnitus.
Did tinnitus loudness improve?
Limited. Observational reports of reduced audibility/awareness; controlled percept-level evidence is weak.
Did tinnitus distress improve?
Moderate. In UNITI 2025 hearing aids were among the largest single-treatment effects on THI; Cochrane 2018 rates the controlled evidence as low quality.
Loudness means the tinnitus percept itself became quieter (psychoacoustic matching or loudness ratings). Distress means questionnaire scores such as THI/TFI, sleep, anxiety or quality of life improved — the sound may be unchanged. A THI/TFI improvement is never evidence the tinnitus got quieter.
How strong is the evidence?
Guideline recommendation and the UNITI head-to-head result earn 3/5; a trial isolating the tinnitus effect from the hearing benefit would settle it. Amplification-SPECIFIC randomized evidence is thin: Cochrane CD010151 found one RCT (N=91) and concluded there is no evidence to support or refute hearing aids as a routine tinnitus intervention; the rating rests on guideline consensus (all three major guidelines recommend aids with hearing loss), UNITI results and observational data.
Has the result been independently replicated?
Limited independent. Benefit signals from independent groups (UNITI, observational), but few amplification-specific RCTs.
What are the limitations?
- Benefit entangled with the hearing benefit itself
- Cochrane: low-quality controlled evidence
- Doesn't help tinnitus with normal hearing
What should patients know about safety?
Safety evidence: Strong. Very safe; main risk is poor fitting.
Is it available?
Regulatory status: FDA regulated (hearing aids); OTC category exists. Regulated as hearing devices, not tinnitus treatments. AAO-HNSF 2014 guideline strength: 'Recommendation' (the middle tier — same as CBT; sound therapy gets only 'Option'). Since Sept 2024, Apple's AirPods Pro Hearing Aid Feature holds its own FDA De Novo authorization as OTC hearing-aid software — a $249 route to amplification for mild-moderate loss (no tinnitus-specific RCT of it exists).
Availability: Widely available; OTC since 2022 for mild-moderate loss · Europe: Widely available; publicly funded in several countries · Cost (approx.): $200 (OTC) – $7,000+/pair (premium fitted)
What the studies found
UNITI-RCT: single versus combined treatments for chronic tinnitus
Schoisswohl S, Basso L, Simoes J, et al. (incl. Langguth B) · Nature Communications · 2025 · N=461 (230 single / 231 combination) · Multicenter RCT, 5 sites in 4 countries
Within-group THI change: −11.7 (single treatments) vs −14.9 (combinations); the between-group difference of ≈3.2 points was statistically significant (p=0.034) but below a ~7-point clinical-meaningfulness benchmark (external literature value — the paper itself does not define this threshold). Paper verbatim: CBT and hearing aids alone had large effect sizes 'which could not be further increased by combination treatment.'
The largest trial ever to compare tinnitus treatments head-to-head. Statistically significant, clinically marginal difference between strategies — the substantive finding is which single treatments performed best.
Sound therapy (amplification devices and sound generators) for tinnitus (Cochrane Review)
Sereda M, et al. · Cochrane Database of Systematic Reviews · 2018 · N=590 (8 trials) · Systematic review of RCTs
Crucially: NO usable data existed for any of the three main comparisons (sound therapy vs waitlist, vs placebo, or vs education alone). The 8 trials only compared device types — hearing aids vs sound generators vs combination devices — with insufficient evidence of any difference (low/very-low certainty).
This is absence of evidence, not 'tested and found no better': trials answering the sound-therapy-vs-placebo question simply have not produced usable data. Sound remains widely used, low-risk, and valued by many patients.
Cochrane: amplification with hearing aids for tinnitus (CD010151)
Hoare DJ, Edmondson-Jones M, Sereda M, Akeroyd MA, Hall D · Cochrane Database of Systematic Reviews · 2014 · N=1 RCT, 91 participants · Cochrane systematic review
Only ONE eligible RCT (N=91, hearing aids vs sound generators — no difference between devices). Verbatim conclusion: 'there is currently no evidence to support or refute their use as a more routine intervention for tinnitus.'
This is why the platform labels amplification-SPECIFIC tinnitus evidence as thin even though hearing aids rank #6: the ranking rests on guideline consensus, UNITI subgroup results and observational data, not on dedicated randomized amplification trials.
AAO-HNSF Clinical Practice Guideline: Tinnitus
Tunkel DE, Bauer CA, Sun GH, et al. · Otolaryngology–Head and Neck Surgery · 2014 · N=Guideline (23-author multidisciplinary panel) · Clinical practice guideline (US)
RECOMMENDS: hearing-aid evaluation (with hearing loss) and CBT for persistent bothersome tinnitus. OPTION: sound therapy ('may recommend'). AGAINST routine use: medical therapy (antidepressants, anticonvulsants, anxiolytics, intratympanic drugs), dietary supplements (Ginkgo, melatonin, zinc), and rTMS. NO RECOMMENDATION: acupuncture.
Guidelines are consensus documents, not new trial data. Where the three major guidelines disagree — chiefly on sound therapy (AAO-HNSF: option; NICE and the European guideline: research-only; the German S3 guideline: against sound generators) — this platform shows the disagreement rather than picking a side. Statement strengths read from the published abstracts; full-text verbatim wording not independently re-read.
NICE guideline NG155: Tinnitus — assessment and management
National Institute for Health and Care Excellence · NICE (UK) · 2020 · N=National guideline · Clinical practice guideline (UK)
Amplification: OFFER with hearing loss affecting communication; CONSIDER with hearing loss without communication difficulty; DO NOT OFFER without hearing loss. Psychological therapies (stepped): digital tinnitus-related CBT → group interventions (MBCT/ACT/CBT) → individual CBT. Betahistine: 'Do not offer betahistine to treat tinnitus.' Sound therapy and neuromodulation: 'We were unable to make recommendations for practice in this area.'
Also advises against psychoacoustic pitch/loudness matching for assessment. Read from the official NICE pathway document (NBK557037 mirror). NICE's sound-therapy position (no practice recommendation) conflicts with AAO-HNSF's 'option' — shown as a disagreement, not resolved by this platform.
European multidisciplinary guideline for tinnitus
Cima RFF, Mazurek B, Haider H, et al. · HNO · 2019 · N=Multinational guideline · Clinical practice guideline (Europe)
CBT: STRONG recommendation FOR. Hearing aids: FOR, with hearing loss. Sound therapy: recommendation for RESEARCH only (no practice recommendation — not an 'against'). Pharmacotherapy: weak recommendation AGAINST. Transcranial electrical stimulation: AGAINST.
Stances verified via a peer-reviewed secondary source (Langguth et al., J Clin Med 2023, PMC10178961) because the primary full text is paywalled; verbatim wording and grading system therefore marked unable-to-verify. Together with AAO-HNSF 2014 and NICE NG155, the three guidelines agree on CBT (for) and drugs (against) and diverge on sound therapy.
Related treatments
- Cochlear implants (for qualifying hearing loss) — For people with severe hearing loss, implantation often genuinely reduces the tinnitus sound itself — one of…
- Combination aids & fractal tones (e.g., Widex Zen) — Hearing aids with built-in tinnitus sounds — sensible, but the tinnitus add-ons lack independent proof.
Evidence last reviewed: 2026-09-03 · Evidence included through: 2026-09-03 · Confidence: high. Open the interactive evidence profile.
This page summarizes published research for education. It is not medical advice; it cannot say what will work for any individual. Discuss treatment decisions with a qualified clinician.